“Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway”, NJPS, c. 40, sy 2, ss. 251–262, Ara. 2025, doi: 10.54548/.